Publication date: Aug 07, 2019
This post was originally published on this site Relapsing-remitting multiple sclerosis (RRMS) patients treated with Lemtrada (alemtuzumab) may develop additional (secondary) autoimmune reactions. Anti-CD20 therapies, including rituximab or Ocrevus (ocrelizumab), are a potential treatment for Lemtrada-associated autoimmune complications in patients who fail to respond to other conventional immunotherapies, according to a case report about two women in Australia. The team considered that the autoimmune reactions in both RRMS patients were caused by an abnormal proliferation of B-cells as a result of Lemtrada treatment. Based on the results, the team suggested that -B-cell depletion therapy should be considered early in the treatment course of patients presenting with severe. ..autoimmune complications of alemtuzumab [Lemtrada],” and that -clinicians should remain vigilant when caring for patients undergoing alemtuzumab treatment,” they wrote. While both patients failed to respond to treatment with conventional immunotherapies, anti-CD20 therapies resulted in remission of secondary autoimmune diseases. Overall, the findings support the use of -anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B-cell hyperpopulation,” the team concluded.
|disease||DOID||Relapsing-remitting multiple sclerosis|
|disease||MESH||Relapsing-remitting multiple sclerosis|